PALATIN TECHNOLOGIES, INC. Selling, General and Administrative Expense
PALATIN TECHNOLOGIES, INC. (PTN) reported Selling, General and Administrative Expense of $1.66 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2025-11-14
- PALATIN TECHNOLOGIES, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $1.66M, a 17.82% decline year-over-year.
- PALATIN TECHNOLOGIES, INC. selling, general and administrative expense for the quarter ending 2025-06-30 was $2.63M, a 34.25% decline year-over-year.
- PALATIN TECHNOLOGIES, INC. selling, general and administrative expense for the quarter ending 2025-03-31 was $1.47M, a 27.51% decline year-over-year.
- PALATIN TECHNOLOGIES, INC. selling, general and administrative expense for the quarter ending 2024-12-31 was $1.68M, a 44.54% decline year-over-year.
- PALATIN TECHNOLOGIES, INC. selling, general and administrative expense for fiscal 2025 was $7.81M, a 36.35% decline from fiscal 2024.
- PALATIN TECHNOLOGIES, INC. selling, general and administrative expense for fiscal 2024 was $12.27M, a 19.76% decline from fiscal 2023.
- PALATIN TECHNOLOGIES, INC. selling, general and administrative expense for fiscal 2023 was $15.29M, a 7.40% decline from fiscal 2022.
- PALATIN TECHNOLOGIES, INC. selling, general and administrative expense for fiscal 2022 was $16.51M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $1.66M 10-Q · filed 2025-11-14 | $4.29M derived: sum of 2 quarters · filed 2025-11-14 | $5.77M derived: sum of 3 quarters · filed 2025-11-14 | $7.45M derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | $2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $4.11M derived: sum of 2 quarters · filed 2025-09-23 | $5.79M derived: sum of 3 quarters · filed 2025-09-23 | $7.81M 10-K · filed 2025-09-23 |
| 2025-03-31 | $1.47M 10-Q · filed 2025-05-14 | $3.16M derived: sum of 2 quarters · filed 2025-05-14 | $5.18M 10-Q · filed 2025-05-14 | $9.18M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-12-31 | $1.68M 10-Q · filed 2025-02-13 | $3.70M 10-Q · filed 2025-02-13 | $7.71M derived: sum of 3 quarters · filed 2025-11-14 | $9.74M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-09-30 | $2.02M 10-Q · filed 2025-11-14 | $6.02M derived: sum of 2 quarters · filed 2025-11-14 | $8.06M derived: sum of 3 quarters · filed 2025-11-14 | $11.09M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $6.04M derived: sum of 2 quarters · filed 2025-09-23 | $9.07M derived: sum of 3 quarters · filed 2025-09-23 | $12.27M 10-K · filed 2025-09-23 |
| 2024-03-31 | $2.03M 10-Q · filed 2025-05-14 | $5.07M derived: sum of 2 quarters · filed 2025-05-14 | $8.27M 10-Q · filed 2025-05-14 | $13.34M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $3.03M 10-Q · filed 2025-02-13 | $6.23M 10-Q · filed 2025-02-13 | $11.30M derived: sum of 3 quarters · filed 2025-02-13 | $14.84M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-09-30 | $3.20M 10-Q · filed 2024-11-14 | $8.27M derived: sum of 2 quarters · filed 2024-11-14 | $11.81M derived: sum of 3 quarters · filed 2024-11-14 | $14.98M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $5.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $8.61M derived: sum of 2 quarters · filed 2024-09-30 | $11.78M derived: sum of 3 quarters · filed 2024-09-30 | $15.29M 10-K · filed 2024-09-30 |
| 2023-03-31 | $3.54M 10-Q · filed 2024-05-15 | $6.71M derived: sum of 2 quarters · filed 2024-05-15 | $10.22M 10-Q · filed 2024-05-15 | $16.57M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $3.17M 10-Q · filed 2024-02-14 | $6.68M 10-Q · filed 2024-02-14 | $13.03M derived: sum of 3 quarters · filed 2024-02-14 | $16.04M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-09-30 | $3.51M 10-Q · filed 2023-11-14 | $9.86M derived: sum of 2 quarters · filed 2023-11-14 | $12.87M derived: sum of 3 quarters · filed 2023-11-14 | $16.18M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $6.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-28 | $9.36M derived: sum of 2 quarters · filed 2023-09-28 | $12.68M derived: sum of 3 quarters · filed 2023-09-28 | $16.51M 10-K · filed 2023-09-28 |
| 2022-03-31 | $3.01M 10-Q · filed 2022-05-16 | $6.33M derived: sum of 2 quarters · filed 2022-05-16 | $10.16M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $3.32M 10-Q · filed 2022-02-14 | $7.15M 10-Q · filed 2022-02-14 | ||
| 2021-09-30 | $3.84M 10-Q · filed 2021-11-15 | |||
| 2021-03-31 | $4.01M 10-Q · filed 2022-05-16 | $9.05M derived: sum of 2 quarters · filed 2022-05-16 | $11.39M 10-Q · filed 2022-05-16 | |
| 2020-12-31 | $5.04M 10-Q · filed 2022-02-14 | $7.38M 10-Q · filed 2022-02-14 | ||
| 2020-09-30 | $2.33M 10-Q · filed 2021-11-15 | |||
| 2020-03-31 | $2.07M 10-Q · filed 2021-05-14 | $4.48M derived: sum of 2 quarters · filed 2021-05-14 | $6.31M 10-Q · filed 2021-05-14 | |
| 2019-12-31 | $2.40M 10-Q · filed 2021-02-16 | $4.24M 10-Q · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |